FACTBOX-World's top-selling drugs in 2014 vs 2010

Tue Apr 13, 2010 9:01am EDT

 April 13 (Reuters) - Roche's (ROG.VX) cancer drug Avastin is
expected to be the world's biggest-selling drug in 2014, as
today's two top blockbusters -- Lipitor and Plavix -- lose
patent protection in 2011 and 2012.
 In four years' time, the prescription drug league table will
look very different, reflecting the growing commercial dominance
of injectable biotech drugs, especially for cancer and
rheumatoid arthritis.
 
 Consensus sales forecasts for world's top 10 drugs in 2014:
 1. Avastin (cancer)        Roche                       $8.9 bln
 2. Humira (arthritis)      Abbott (ABT.N)              $8.5 bln
 3. Enbrel  (arthritis)     Pfizer(PFE.N)/Amgen(AMGN.O) $8.0 bln
 4. Crestor (cholesterol)   AstraZeneca (AZN.L)         $7.7 bln
 5. Remicade (arthritis)    Merck(MRK.N)/J&J(JNJ.N)     $7.6 bln
 6. Rituxan (cancer)        Roche                       $7.4 bln
 7. Lantus (diabetes)       Sanofi-Aventis (SASY.PA)    $7.1 bln
 8. Advair (asthma/COPD)    GlaxoSmithKline (GSK.L)     $6.8 bln
 9. Herceptin (cancer)      Roche                       $6.4 bln
 10.NovoLog (diabetes)      Novo Nordisk (NOVOb.CO)     $5.7 bln
 
 Consensus forecasts for 2010:
 1. Lipitor (cholesterol)   Pfizer                     $11.7 bln
 2. Plavix (anticlotting)   Sanofi/Bristol (BMY.N)      $9.6 bln
 3. Advair (asthma/COPD)    GlaxoSmithKline             $9.0 bln
 4. Remicade (arthritis)    Merck/J&J                   $7.4 bln
 5. Enbrel (arthritis)      Pfizer/Amgen                $7.1 bln
 6. Humira (arthritis)      Abbott                      $6.8 bln
 7. Avastin (cancer)        Roche                       $6.7 bln
 8. Rituxan (cancer)        Roche                       $6.1 bln
 9. Diovan (hypertension)   Novartis                    $6.0 bln
 10.Crestor (cholesterol)   AstraZeneca                 $5.8 bln
 
 Source: Thomson Reuters
(Reporting by Ben Hirschler, Editing by Sitaraman Shankar)


FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

Retirement Road Map